Part the Cloud Translational Gene Targeting Challenge Grant

Part the Cloud Translational Gene Targeting Challenge Grant

Status: ACTIVE
Funder: Alzheimer's Association
Amount: Up to US $2,000,000
Last Updated: November 22, 2025

Summary

The Alzheimer's Association's Part the Cloud Translational Gene Targeting Challenge Grant aims to enhance early-phase human trials (Phase 1 and Phase 2) for therapies targeting the genetic causes of Alzheimer's disease and related dementias. With funding up to $2 million, it encourages innovative research internationally, with a focus on at least 10 clinical trials. This initiative represents a significant step towards advancing Alzheimer’s research and improving patient outcomes.

Overview

Alzheimer’s Association The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Part the Cloud Translational (PTC) Gene Targeting Challenge Grant Part the Cloud, a program through the Alzheimer's Association, announces a targeted challenge funding program focused on increasing early phase human trials (Phase 1 and Phase 2) of potential therapies tailored to the genetic underpinnings of Alzheimer’s disease and related dementias internationally. Funding Each grant is limited to $1,000,000 (direct and indirect costs) for Phase 1 studies and $2,000,000 for Phase 2 studies over two or three years. We anticipate funding a mix of phase 1 and phase 2 studies with available funding, minimum of 10 clinical trials. Indirect costs are only allowed for not for-profit institutions, and are capped at 10 percent (rent for laboratory/office space is expected to be covered by indirect costs paid to the institution). No indirect costs are allowed for profit organizations.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.